Artesunate-amodiaquine
Trials 7 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT06076213 | May 2023 → Sep 2024 | Plasmodium falciparum malaria | Ministry of Public Health, Democratic Republic of the Congo | Completed | No outcome recorded |
| Phase 4 | NCT03431714 | Jul → Dec 2017 | Plasmodium falciparum malaria | National Institute for Medical Research, Tanzania | Completed | No outcome recorded |
| Phase 4 | NCT02637128 | Mar → Jul 2014 | Plasmodium falciparum malaria | Centers for Disease Control and Prevention | Completed | No outcome recorded |
| Phase 4 | NCT01755559 | Jun 2013 → Nov 2014 | malaria | Epicentre | Completed | No outcome recorded |
| Phase 4 | NCT01213433 | Oct → Nov 2010 | malaria | Centre Muraz | Completed | No outcome recorded |
| Phase 4 | NCT00808951 | Dec 2008 → Oct 2010 | malaria | Centre Muraz | Completed | No outcome recorded |
| Phase 4 | NCT01017770 | Sep 2008 → Jan 2010 | Plasmodium falciparum malaria | Centre Muraz | Completed | No outcome recorded |
Also used as a comparator or background therapy in 3 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 32 trials | ||||||
| Phase 3 | NCT03640403 Comparator | Mar 2019 → Dec 2020 | Plasmodium falciparum malaria, anemia | National Institute for Medical Research, Tanzania | Completed | No outcome recorded |
| Phase 3 | NCT00852423 Comparator | Jun 2010 → Oct 2013 | Plasmodium falciparum malaria | Institute of Tropical Medicine, Belgium | Completed | No outcome recorded |
| Phase 41 trial | ||||||
| Phase 4 | NCT01350856 Comparator | May 2011 → Apr 2014 | Plasmodium falciparum malaria | University of Oxford | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 11 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Artesunate amodiaquine | “The study assessed the efficacy and safety of artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP) for the treatment of uncomplicated malaria in Tanzania.” NCT03431714 ↗10“Artesunate 2 mg/kg/day for 3 days followed by a full course of either artemether-lumefantrine or DHA-piperaquine or artesunate-mefloquine or artesunate-amodiaquine” NCT01350856 ↗ “Artesunate amodiaquine” NCT03431714 ↗ |
| Known as | AQ+AS | “Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008.It is administered once daily for three consecutive days, and it is available in three different...” NCT01213433 ↗1“Burkina Faso has changed its policy for uncomplicated malaria to Artemether-Lumefantrine (AL) and Artesunate-Amodiaquine (AQ+AS)” NCT00808951 ↗ |
| Known as | AQAS, artesunate-amodiaquine Winthrop | “AQAS, artesunate-amodiaquine Winthrop®” NCT00852423 ↗ |
| Known as | AS-AQ Winthrop | “A WHO standard protocol was used to assess efficacy of the combinations artesunate-amodiaquine (AS-AQ Winthrop®), dihydroartemisinin-piperaquine (DHA-PPQ, Eurartesim®) and...” PMID 29370844 ↗ Jan 2018 |
| Known as | ASAQ | “The study assessed the efficacy and safety of artesunate-amodiaquine (ASAQ) and dihydroartemisinin-piperaquine (DP) for the treatment of uncomplicated malaria in Tanzania.” NCT03431714 ↗3“Artesunate-amodiaquine (ASAQ). One of the Artemisinin combination therapy(ACTs), indicated for treatment of uncomplicated malaria.” NCT03640403 ↗ “Artesunate-amodiaquine(AS-AQ), according to one of the two options given by national protocol in Burkina Faso” NCT00808951 ↗ “Drug: artesunate-amodiaquine (ASAQ)” NCT02637128 ↗ |